Navigation Links
InspireMD Reports Financial Results For Period Ended March 31, 2013
Date:5/8/2013

corded in the same period in 2012. The increase was the result of improved selling activities in key European countries. 

--Gross profit for the March 31, 2013 period increased 49% to $840,000, compared to $564,000 for the March 31, 2012 period. The increase was due to higher revenue and gross margins, which increased from 50% to 55% due to a higher average selling price and lower cost per unit sold.

--Total operating expenses for the March 31, 2013 period were $4.1 million, compared to $3.7 million in the March 31, 2012 period, an increase of $400,000. With enrollment for the MASTER I trial completed, as well as a timing gap between the pre-clinical phase and the start of the recruitment phase of the FDA trial, R&D expenses for the March 31, 2013 period decreased by approximately $500,000, or 33%, compared to the March 31, 2012 period. This decrease was offset by an 81% increase in sales and marketing expenses as we expanded our sales activities worldwide, and a 23% increase in G&A expenses due mainly to an increase in share-based compensation and salary expenses.

--The loss from operations for the March 31, 2013 period was $3.2 million, compared to $3.1 million for the March 31, 2012 period.

--The net loss for the period ended March 31, 2013 totaled $4.9 million, or $0.27 per basic and diluted share, compared to a net loss of $3.1 million, or $0.18 per basic and diluted share in the period ended March 31, 2012. The increased net loss for the quarter just ended resulted primarily from a roughly $400,000 increase in operating expenses, and $1.7 million in financial expenses related to debenture amortization costs and anti-dilution rights expenses. The weighted average number of shares of common stock used in computing net loss per share (basic and diluted) was 18.2 million for the quarter ended March 31, 2013, and 17 million for the quarter ended March 31, 2012.

--At March 31, 2013, cash and cash equivalents was appro
'/>"/>

SOURCE InspireMD, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. InspireMD Receives Approval From US Food and Drug Administration to Begin US Regulatory Trial
2. InspireMD Closes $25 Million Underwritten Public Offering
3. InspireMD Announces Pricing of Underwritten Public Offering of Common Stock and Listing on NYSE MKT
4. InspireMD Receives CE Mark Approval for Carotid Embolic Protection Stent
5. InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
6. InspireMD Reports Results for Period Ended Dec. 31, 2012
7. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
8. Positive Results of InspireMDs MASTER Trial to be Published on November 6 in Journal of American College of Cardiology
9. InspireMD Reports Results For Period Ending Sept. 30, 2012
10. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
11. InspireMD to Present at Harvard Investors Group on June 27 in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... ALISO VIEJO, Calif. , Dec. 22, 2014 /PRNewswire/ ... moved into expanded corporate offices in Aliso ... President, announced that due to the tremendous growth and ... critically needed. Sales of patented SnoreRx, the anti snore ... administrative offices. He said, "We are now in ...
(Date:12/22/2014)...   TRU-D SmartUVC LLC, producers of the ... today that the General Services Administration has awarded the ... This newly formed agreement will allow TRU-D ... purchasers, including Department of Veteran Affairs and Department of ... purchasing solutions for the Ebola effort in ...
(Date:12/22/2014)...  ConvaTec, a privately-held medical products and technologies company, ... Chief Executive Officer of the company, effective December 22, ... .  "The Board of Directors of ConvaTec thanks Mr. ... past three years," said Magnus Lundberg , the ... that the company is well positioned for the future."  ...
Breaking Medicine Technology:TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
... 1, 2011 Reportlinker.com announces that a ... its catalogue: Cancer ... Forecasts to 2017 ... Therapeutics - Pipeline Assessment and Market Forecasts ...
... YORK, June 1, 2011 Reportlinker.com announces that ... its catalogue: China,s Guidebook for ... China,s-Guidebook-for-Pharmaceutical-Patent-Protection.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication Description China ... market in the world by 2010 with a ...
Cached Medicine Technology:Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017 3Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017 4Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017 5Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017 6Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017 7Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017 8Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017 9Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017 10Reportlinker Adds China's Guidebook for Pharmaceutical Patent Protection 2Reportlinker Adds China's Guidebook for Pharmaceutical Patent Protection 3Reportlinker Adds China's Guidebook for Pharmaceutical Patent Protection 4Reportlinker Adds China's Guidebook for Pharmaceutical Patent Protection 5Reportlinker Adds China's Guidebook for Pharmaceutical Patent Protection 6
(Date:12/25/2014)... The microscopy market is estimated to ... $5,756.0 million by 2019. Optical microscopy is the ... microscopes product segment is expected to show the ... focus on nanotechnology, technological advancements, and increasing federal ... , Get Full Copy of Report @ ...
(Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) ... on the current treatment landscape, unmet needs, current ... market. Stivarga is a drug which is used ... Boehringer Ingelheim is developing nintedanib (BIBF-1120), an orally ... CRC in the US, Europe, and Japan. The ...
(Date:12/25/2014)... “Every three months the trends for evening dresses ... be one of the hottest styles in the next few ... company releases 26 A-line sweetheart evening dresses, and announces the ... “We are trying our best to help a lady to ... with affordable prices, we provide discounted delivery costs to our ...
(Date:12/25/2014)... 25, 2014 The short film “Color of ... in honor of a true 9/11 hero, Welles Remy Crowther. ... including the 24 hours of Nuremberg International Short Film Festival ... , Actress, screenwriter and director Luciana Lagana plays ... together with her husband, Gregory Graham - Graham ...
(Date:12/25/2014)... 2014 Helen Harris’ RP (Retinitis Pigmentosa) ... California after an 8 year battle with breast cancer. ... evening in her home in Woodland Hills California after ... , As the founder and volunteer ... pioneered and championed many of today's greatest breakthroughs in ...
Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... , WEDNESDAY, Feb. 1 (HealthDay News) -- Child abuse and ... is comparable to the costs of other major public health ... U.S. Centers for Disease Control and Prevention analyzed 1,740 fatal ... of one year. The investigators found that the lifetime ...
... Ore. Researchers have developed a type of wearable, non-invasive ... rate and respiration at the same time it records a ... and patient care. The device is just two inches ... with the skin and can operate for a week without ...
... , WEDNESDAY, Feb. 1 (HealthDay News) -- About one ... the United States by Pfizer Inc. because of a packaging ... cause unintended pregnancies. The recall of 14 lots of ... Estradiol tablets was announced late Tuesday after Pfizer discovered that ...
... WEDNESDAY, Feb. 1 (HealthDay News) -- Many adults whose parents ... brain aging in middle age that may precede a stroke, ... with an average age of 61 who underwent MRI brain ... the volume of white matter lesions and other signs of ...
... ) publishes online and in print today a ... form cutting-edge genomic and epigenomic analyses of cancer. ... biological insights gained from genomic analyses of pancreatic ... analyses of breast cancer genes, large scale colorectal ...
... that can cause inflammation and organ failure, has different ... why some people are very susceptible to the infection, ... they could study liver cells from different people in ... these varying responses. However, liver cells are difficult to ...
Cached Medicine News:Health News:Child Abuse, Neglect a Major Public Health Problem: CDC 2Health News:Pfizer Recalls 1 Million Packets of Birth Control Pills 2Health News:Adult Children of Stroke Sufferers May Show Signs of Brain Aging, Too 2Health News:Genome Research publishes special issue: Cancer Genomics 2Health News:Genome Research publishes special issue: Cancer Genomics 3Health News:Genome Research publishes special issue: Cancer Genomics 4Health News:Genome Research publishes special issue: Cancer Genomics 5Health News:Genome Research publishes special issue: Cancer Genomics 6Health News:Genome Research publishes special issue: Cancer Genomics 7Health News:MIT: Stem cells could drive hepatitis research forward 2Health News:MIT: Stem cells could drive hepatitis research forward 3
The latex-free, PVC-free Antibacterial Hydro Personal catheter combines two remarkable innovations into one exclusive catheter that delivers an antibacterial agent while providing the virtually frict...
The Antibacterial Personal Catheter® features a unique silicone composition that provides an antibacterial coated soft outer layer of silicone combined with a firm inner layer....
The Uro San® Plus male external catheter is a latex catheter with a double-sided adhesive and Shield Skin Protective Dressing....
... Pak Seven Starter Kit: a ... of Freedom Clear catheters and ... 100% latex-free along with ... convenience and comfort. Plus each ...
Medicine Products: